As EPHA7, NTRK3, ZFHX3, and PTPRD mutations were all associated with improved outcomes in NSCLC patients in the discovery cohort, we next explored whether this relationship was also observed in a validation cohort consisting of 91 NSCLC patients also receiving ICIs. The gene discussed is PTPRD; the disease is non-small cell lung carcinoma.